A member of the firm's White Collar Litigation and Investigations group, Debra Schreck has significant experience representing clients in complex investigations and litigation matters.

Ms. Schreck represents and counsels pharmaceutical and medical device companies in connection with criminal and civil investigations by federal and state government agencies, including the US Department of Justice, US Attorneys' Offices and state Attorneys General. Ms. Schreck defends clients in federal and state white collar litigation, including actions brought under the qui tam provisions of the False Claims Act and involving the Food, Drug & Cosmetic Act, the Anti-Kickback Statute and other healthcare statutes and regulations. Ms. Schreck also conducts and counsels clients in connection with large-scale internal investigations and internal training programs.

In addition to her expertise in healthcare, Ms. Schreck leads internal investigations for corporations and institutions related to workplace issues, including allegations of harassment and other misconduct. Ms. Schreck serves on the firm's Recruiting Committee and is active in the firm's mentoring program.


  • Eli Lilly and Company, Inc. in qui tam suit brought by a relator in Eastern District of Texas, alleging kickback claims in connection with nurse education and reimbursement support programs.
  • Novartis Pharmaceuticals Corporation and Novartis Corporation in qui tam suit brought in District of Massachusetts by multiple relators, alleging off label promotion and kickback claims in connection with the asthma medication, Xolair®. On a motion to dismiss, obtained dismissal with prejudice of all claims. US ex rel. Garcia v. Novartis AG, 91 F. Supp. 3d 87, 97 (D. Mass. 2015). Dismissal with prejudice of all federal claims was affirmed by the First Circuit. US ex rel. Kelly v. Novartis Pharm. Corp., 827 F.3d 5 (1st Cir. 2016).
  • Major brand name prescription drug manufacturer in qui tam litigation brought in Southern District of New York by government and relator, alleging kickbacks to specialty pharmacies in connection with various medications.
  • Bayer Corporation, Bayer HealthCare Pharmaceuticals Inc. and Merck & Co. Inc., in federal and state product liability litigation involving two fluoroquinolone antibiotics, Avelox® and Cipro®.


Pharmaceutical and Medical Device Investigations and Enforcement Forum
Arnold & Porter Seminar, Short Hills, NJ
Not-So-Common Interest: Privilege Claim by Relator and Government Runs Aground
Qui Notes: Unlocking the False Claims Act
Deskbook on Internal Investigations, Corporate Compliance, and White Collar Issues (2nd ed.)
Practising Law Institue
Deskbook on Internal Investigations, Corporate Compliance and White Collar Issues (2nd Edition)
PLI Practising Law Institute
DOJ Gets Practical on Corporate Resolutions: Highlights From Rod Rosenstein's November 29th Comments on Individual Accountability
Qui Notes: Unlocking the False Claims Act


  • JD, Fordham University School of Law, 2006, magna cum laude, Order of the Coif
  • BA, Yeshiva University, 2003, summa cum laude, Valedictorian
  • New York
  • New Jersey
  • US Court of Appeals for the First Circuit
  • US District Court, Southern District of New York
  • US District Court, Eastern District of New York
  • US District Court, District of New Jersey

Email Disclaimer